On December 10, 2021, Dizhe Pharmaceutical, a portfolio company of a sub-fund backed by the master fund managed by Yuanhe Chenkun—Lilly Asia Ventures—successfully listed on the STAR Market, with stock code: 688192.

Dizhe Pharma, founded in 2017, is a globally innovative biopharmaceutical company with products currently in clinical development. The company focuses on the research, development, and commercialization of cutting-edge drugs targeting malignant tumors and immune-related diseases.

Dizhe Pharmaceutical adheres to a research and development philosophy centered on pioneering innovation, dedicating itself to uncovering novel targets and validating their mechanisms of action. With the goal of bringing forth first-in-class drugs and breakthrough therapies with transformative potential, the company strives to address unmet clinical needs and set the pace for industry-wide advancements.

The company’s two fastest-progressing products—DZD4205, targeting peripheral T-cell lymphoma, and DZD9008, designed for non-small cell lung cancer patients with EGFR/HER2 exon 20 insertion mutations—are both now advancing into pivotal, international, multi-center clinical trials. Both candidates are expected to submit marketing applications in 2023 to regulatory authorities such as the U.S. FDA and China’s NMPA, among other regions.

Moving forward, the company will remain committed to independent innovation, accelerate clinical development of its existing product pipeline, and expedite the implementation of its internationalization strategy. We will actively explore and expand into overseas markets, continuously strengthening the company’s market position in both domestic and global biopharmaceutical industries, as well as enhancing our international competitiveness.